MiMedx Group (MDXG) to Release Earnings on Wednesday

MiMedx Group (NASDAQ:MDXG - Get Free Report) is anticipated to post its Q1 2025 quarterly earnings results after the market closes on Wednesday, April 30th. Analysts expect the company to announce earnings of $0.06 per share and revenue of $86.32 million for the quarter.

MiMedx Group (NASDAQ:MDXG - Get Free Report) last posted its earnings results on Wednesday, February 26th. The company reported $0.07 earnings per share for the quarter, meeting the consensus estimate of $0.07. The company had revenue of $92.91 million for the quarter, compared to analyst estimates of $89.42 million. MiMedx Group had a return on equity of 26.21% and a net margin of 23.86%. On average, analysts expect MiMedx Group to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

MiMedx Group Price Performance

NASDAQ MDXG traded down $0.09 during trading hours on Monday, reaching $6.83. The company's stock had a trading volume of 33,228 shares, compared to its average volume of 684,020. The company has a debt-to-equity ratio of 0.10, a quick ratio of 3.53 and a current ratio of 4.10. The company's 50-day moving average is $7.53 and its two-hundred day moving average is $8.07. MiMedx Group has a fifty-two week low of $5.47 and a fifty-two week high of $10.14. The stock has a market cap of $1.01 billion, a PE ratio of 12.43 and a beta of 1.74.

Insider Buying and Selling

In other MiMedx Group news, CAO William Frank Iv Hulse sold 81,446 shares of the firm's stock in a transaction dated Monday, March 10th. The stock was sold at an average price of $7.80, for a total value of $635,278.80. Following the sale, the chief accounting officer now directly owns 494,774 shares of the company's stock, valued at approximately $3,859,237.20. This trade represents a 14.13 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Kimberly Maersk-Moller sold 4,106 shares of the company's stock in a transaction dated Thursday, March 13th. The shares were sold at an average price of $7.89, for a total transaction of $32,396.34. Following the transaction, the insider now directly owns 310,836 shares of the company's stock, valued at approximately $2,452,496.04. This represents a 1.30 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 144,018 shares of company stock worth $1,130,312. 1.30% of the stock is owned by insiders.

Analyst Ratings Changes

MDXG has been the subject of several research reports. StockNews.com downgraded MiMedx Group from a "strong-buy" rating to a "buy" rating in a research report on Wednesday, April 16th. Cantor Fitzgerald reiterated an "overweight" rating and set a $13.00 price objective on shares of MiMedx Group in a research report on Thursday, February 27th.

MiMedx Group Company Profile

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins.